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The most common mutation causing cystic fibrosis
(CF), F508del, impairs conformational maturation of
CF transmembrane conductance regulator (CFTR),
thereby reducing its functional expression on the
surface of epithelia. Corrector compounds including
C18 (VRT-534) and VX-809 have been shown to
partially rescue misfolding of F508del-CFTR and
to enhance its maturation and forward trafficking to
the cell surface. Now, we show that there is an addi-
tional action conferred by these compounds beyond
their role in improving the biosynthetic assembly.
In vitro studies show that these compounds bind
directly to the metastable, full-length F508del-CFTR
channel. Cell culture and patient tissue-based
assays confirm that in addition to their cotransla-
tional effect on folding, certain corrector compounds
bind to the full-length F508del-CFTR after its partial
rescue to the cell surface to enhance its function.
These findings may inform the development of
alternative compounds with improved therapeutic
efficacy.
INTRODUCTION
The field of cystic fibrosis (CF) research has been galvanized by
the discovery of a new compound called VX-770 or KALYDECO
(ivacaftor; Vertex Pharmaceuticals), a compound described as a
‘‘potentiator’’ because it repairs the defective channel function
caused by the mutation G551D, a relatively rare mutation found
in <4% of the CF patient population (Accurso et al., 2010; Van
Goor et al., 2009). KALYDECO was approved as a drug for the
treatment of CF patients with this mutation because it was effec-
tive in improving their lung function (Accurso et al., 2010; Van
Goor et al., 2009).666 Chemistry & Biology 21, 666–678, May 22, 2014 ª2014 ElsevierThe major CF mutation, F508del, leads to misfolding of the
CF transmembrane conductance regulator (CFTR) protein
and to its retention and degradation in the endoplasmic
reticulum (Cheng et al., 1990). This defect can be partially
ameliorated in cultured cells by incubating them at low
temperatures (27C) (Denning et al., 1992; Du and Lukacs,
2009; Du et al., 2005; Lukacs and Verkman, 2012). VX-770 or
KALYDECO is effective in potentiating the channel function
of F508del-CFTR after its primary defect in folding has been
partially ameliorated (Eckford et al., 2012; Van Goor et al.,
2009).
Small molecules, called ‘‘corrector compounds,’’ have been
identified that partially recapitulate the ‘‘rescue’’ effect of low
temperature and mediate improved folding and functional
expression of F508del-CFTR in recombinant expression sys-
tems (Pedemonte et al., 2005). Recently, certain small-molecule
‘‘corrector’’ compounds have also been shown to partially
rescue the functional expression of F508del-CFTR on the apical
membrane of epithelia in patient-derived airway cultures,
providing the rationale for clinical trials of the best compounds,
including VX-809 (Van Goor et al., 2011). In clinical trials, VX-809
treatment evoked an increase in the functional expression of
F508del-CFTR in the sweat duct, reported as a significant
decrease in sweat chloride values (Clancy et al., 2012). Although
supporting the principle that such treatments correct the pri-
mary defect in affected patients, VX-809 did not cause signifi-
cant improvements in the major clinical biomarkers of CF
disease in the lung, including forced expiratory volume in
1 second. Hence, more effective therapeutic compounds are
required. We hypothesized that an understanding of the mech-
anism of action of VX-809 and other structurally related
corrector compounds, including C18 (or VX-661 in clinical trials),
will inform the development of compounds with improved ther-
apeutic efficacy.
Recent studies have shed considerable light on the potential
mechanism of action of the structurally related compounds
VX-809 and C18 (Farinha et al., 2013; He et al., 2013; Loo
et al., 2013; Okiyoneda et al., 2013; Ren et al., 2013). The
application of in silico docking methods revealed potentialLtd All rights reserved
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Corrector Compounds and Metastable F508del-CFTRbinding sites on the full-length protein (Farinha et al., 2013; He
et al., 2013; Loo et al., 2013; Okiyoneda et al., 2013; Ren
et al., 2013). The full-length CFTR protein is a multidomain
membrane protein, consisting of two halves, each composed
of a membrane-spanning domain (MSD) and a nucleotide
binding domain (NBD), with the two halves being linked by a
phosphorylation regulated (R) domain. The MSDs assemble
to form the anion-selective channel pore, and the dimerizing
NBDs mediate ATP binding, hydrolysis, and ATP-dependent
channel gating by the phosphorylated CFTR protein (Csana´dy
et al., 2011; Hwang and Sheppard, 2009; Kidd et al., 2004;
Riordan, 2008; Wang et al., 2011). Interestingly, ATP-indepen-
dent channel gating by phosphorylated CFTR has also been
described (Eckford et al., 2012; Jih and Hwang, 2013; Wang
et al., 2007). The F508del mutation in NBD1 is thought to
confer multiple conformational defects in the full-length
CFTR protein because it disrupts the thermostability of
NBD1 (Protasevich et al., 2010; Wang et al., 2010) and per-
turbs the native interaction between NBD1 and the coupling
helix extended from MSD2 (Loo and Clarke, 2011; Loo and
Clarke, 2006; Mendoza et al., 2012; Rabeh et al., 2012; Sero-
hijos et al., 2008). These defects and possible additional
conformational disruptions are thought to contribute to the
misassembly and thermodynamic instability of the full-length
F508del-CFTR protein (Grove et al., 2009; Loo et al., 2009).
The aforementioned in silico docking studies suggest that
VX-809 may bind to F508del-CFTR at certain domain-domain
interfaces (i.e., the interface between F508del-NBD1 and the
coupling helix of MSD2 (or intracellular loop 4 [ICL4]) and/or
intracellular loop 1 of MSD1. To date, however, there
have been conflicting reports regarding the consequences of
mutations at the NBD1-ICL4 interface (including R1070W)
on the efficacy of VX-809 in in-cell maturation studies (He
et al., 2013; Okiyoneda et al., 2013), prompting speculation
that VX-809 may not bind directly to this site on the mutant
protein.
Recent planar lipid bilayer studies of the channel activity of
F508del-CFTR (bearing second site mutations) and in biological
membrane vesicles sought to show that VX-809 directly inter-
acted with the mutant protein by evaluating the consequences
of this compound on F508del-CFTR channel activity. These au-
thors found that the regulated channel activity of F508del-CFTR
was protected from thermal inactivation at 37C by acute treat-
ment with VX-809 (Okiyoneda et al., 2013). These findings were
interpreted to suggest that VX-809 and C18 bind directly to
F508del-CFTR. However, these findings conflict with results
of a similar study of F508del-CFTR channel activity conducted
by He et al. (2013), wherein these compounds failed to modify
thermal sensitivity of the mutant protein bearing other second
site mutations. This discrepancy may relate to the impact of
different second site mutations and/or differential interactions
with F508del-CFTR with thermally sensitive chaperone
proteins. We reasoned that our understanding of the mecha-
nism of action of corrector compounds would benefit from
studies of purified full-length Wt-CFTR and F508del-CFTR
protein (lacking secondary mutations) and extracted from
chaperone proteins. Such studies are essential to determine if
these corrector compounds act directly on the mutant CFTR
protein.Chemistry & Biology 21,RESULTS
The Small Molecule C18 Is Effective in Enhancing the
Functional Expression of F508del-CFTR in the Apical
Membrane of Primary Respiratory Epithelial Cultures
C18 is structurally related to VX-809, a small molecule currently
in clinical trials in patients harboring the F508del mutation (He
et al., 2013; Okiyoneda et al., 2013). C18 (also known as VRT-
534; structure shown in Figure S1A available online) is freely
available to the research community through Cystic Fibrosis
Foundation Therapeutics (CFFT). We confirmed that treatment
of stably transfected baby hamster kidney (BHK) cells with either
VX-809 or C18, usingmaximally effective concentrations recom-
mended by CFFT or defined experimentally (Figures S1B and
S1C) for 24 hr at 37C, led to the enhanced appearance of the
core-glycosylated (Figures S1D andS1Ei) and complex-glycosy-
lated (Figures S1D and S1Eii) forms of the mutant protein. We
probed the structural properties of the C18-rescued mutant pro-
tein (rescued at 37C) by assessing its protease resistance in
membrane vesicles. Our studies shown in Figures S2A and
S2B confirm that the full-length F508del-CFTR protein in crude
membranes exhibits decreased protease (trypsin) resistance
relative to Wt-CFTR protein (Du and Lukacs, 2009; Du et al.,
2005). The C18-rescued, full-length F508del-CFTR protein ex-
hibited a modest increase in protease resistance, significant
only at 1.6 mg/ml trypsin in three independent studies (trypsin
concentrations required to achieve half digestion of full-length
CFTR are reported in the inset of Figure S2Bi). The protein frag-
ments resulting from trypsin digestion were probed using the
domain-specific antibodies L12B4 (NBD1) and M3A7 (NBD2).
As evident in the immunoblots shown in Figure S2 and the quan-
tification of three independent studies in Figures S2Bii and
S2Biii, the abundance of neither the dominant NBD1 fragment
(approximately 38 kD) nor the dominant NBD2 fragment (approx-
imately 25 kD) was enhanced by C18 treatment. This result con-
trasts with findings of He et al. (2013) showing that treatment with
the structurally related VX-809 compound led to protease resis-
tance of the NBD2 fragment. However, these previous studies
were performed using F508del-CFTR protein expressed in cells
subjected to both temperature rescue (at 27C) and VX-809, two
interventions thatmay exert a synergistic effect on the conforma-
tional maturation of F508del-CFTR. Finally, our results support
the conclusion that C18 is only partially effective in correcting
the F508del-CFTR folding defect, more so bymodifying intramo-
lecular assembly rather than through conformational stability of
each individual domain.
Further, C18 is partially effective in promoting the functional
expression of F508del-CFTR in primary respiratory epithelial cul-
tures maintained at 37C. First, we compared the localization of
Wt-CFTR in primary cultures generated from non-CF patients
with the localization of F508del-CFTR in primary cultures homo-
zygous for this mutation. As shown in Figures 1A and 1B, the
well-known trafficking defect of the major mutant is recapitu-
lated in our comparative studies of primary respiratory epithelial
cultures from CF (F508del homozygous) and non-CF transplant
patients. As expected, Wt-CFTR protein is clearly visible on the
apical membrane of surface epithelial cells in non-CF cultures
(representative of labeling studies in cultures obtained from
three different non-CF lung donors; Figure 1B). The intensity of666–678, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 667
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Figure 1. C18 Treatment Rescues the Func-
tional Expression of F508del-CFTR in Primary
Cultures Derived from CF Patients
(A) Upper micrograph showing expression of Wt-
CFTR (labeled green) on primary cultures obtained
from non-CF (normal bronchial epithelial [NBE])
donor. The tight junction protein, ZO-1, is labeled
red and the nuclei with DAPI. The scale bar repre-
sents 10 mm. Most (>50%) of the individual respi-
ratory epithelial cells in non-CF cultures (NBE, n = 3
cultures) exhibited CFTR-specific immunoreactivity
proximal to the apical membrane. Middle and lower
micrographs show paired primary cultures from a
single CF donor, treated with either DMSO or C18
(6 mM) for 48 hr at 37C, with fresh C18 or DMSO
given at the 24 hr point. The cultures were
processed, and F508del-CFTR localization was
assessed by immunofluorescence. CFBE, CF
bronchial epithelial.
(B) The abundance of CFTR-specific immunofluo-
rescence in the apical membrane was determined
for three non-CF cultures and three F508del/
F508del cultures (treated with DMSO or C18
[6 mM]). The CFTR-specific signal was measured
as the fluorescence in the apical membrane minus
the nonspecific signal in the basolateral membrane
using the ‘‘profile’’ tool in ImageJ software, with
three measurements obtained for each culture.
The C18-treated cultures exhibited enhanced
apically localized F508del-CFTR protein relative to
the paired DMSO-treated cultures (means and
SEMs shown in bar graph, **p < 0.01). AU, arbi-
trary units.
(C) Representative Ussing chamber studies
comparing the response to agonists of CFTR
channel function (forskolin, IBMX, and genistein) in vehicle-treated or C18 (6 mM)-treated primary cultures obtained from the same CF donor (homozygous
for the major mutation, n = 7). The CFTR inhibitor (CFTRinh-172 [5 mM]) was added to the apical compartment following stimulation.
(D) This scattergram shows the total CFTR-mediated short circuit circuits as the change caused by the addition of CFTRinh-172 after stimulation with cyclic
AMP agonists for non-CF cultures (solid squares, n = 24 with mean shown). Paired cultures from patients homozygous for F508del were treated with DMSO
or C18 for 48 hr (n = 11). Scattergrams and means are shown. Long-term treatment with C18 caused a significant increase in total CFTR-mediated currents in
these paired studies (***p < 0.001).
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Corrector Compounds and Metastable F508del-CFTRWt-CFTR immunofluorescence in apical membranes relative to
basolateral membrane (apical minus basolateral signal) was
determined for each culture, as described in Experimental Pro-
cedures. As expected, the relative CFTR immunofluorescence
signal at the apical surface was significant less in micrographs
obtained from primary cultures from CF lung donors (F508del/
F508del). Interestingly, in paired studies, we detected an in-
crease in the relative CFTR immunofluorescence signal in the
apical membrane (apical-basolateral signal) after treatment of
cultures from three different CF donors (F508del/F508del) with
C18 for 48 hr at 37C relative to cultures treated with the vehicle
alone. These results show that chronic C18 treatment causes an
increase in the apical expression of CFTR in cultures from these
lung donors.
To complement the immunofluorescence studies, we exam-
ined the efficacy of C18 compared with vehicle (DMSO) in
enhancing F508del-CFTR function in cultures obtained from
11 different patients, who carried two copies of the F508del
mutation (Figure 1D). These studies were performed in a paired
fashion with cultures from each transplant patient being treated
with either C18 or DMSO for 48 hr at 37C (with fresh C18 or
DMSO given at the 24 hr point) prior to study in the Ussing668 Chemistry & Biology 21, 666–678, May 22, 2014 ª2014 Elsevierchamber. Ussing chamber studies were performed using sym-
metrical NaCl solutions, bathing both the apical and basolateral
membranes. F508del-CFTR function was assessed as the
magnitude of transepithelial short circuit currents (Isc) that are
inhibited by the CFTR inhibitor (CFTRinh-172) after stimulation
with the cyclic AMP agonists forskolin and isobutylmethylxan-
thine (IBMX). The magnitude of F508del-CFTR function in cul-
tures that were treated with C18 was significantly greater
than in control, vehicle-treated cultures (p < 0.001) (Figures
1C and 1D). Interestingly, the magnitude of the response was
highly variable. Large variability in the magnitude of CFTR-
dependent currents was also observed in studies of 24 non-
CF cultures (Figure 1D), possibly reflecting variations in genetic
background and/or non-CF lung disease. However, compari-
son of non-CF cultures with C18-treated CF cultures supports
the claim that partial but significant rescue can be achieved
in primary CF tissues using this small molecule. The extent of
functional rescue caused by long-term incubation with C18
was approximately 20% of the mean CFTR function measured
in non-CF cultures, close to the efficacy reported for VX-
809, the related compound in a clinical trial (Van Goor et al.,
2011).Ltd All rights reserved
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Figure 2. C18 Binds Directly to Promote
Channel Activation of Purified, Phosphory-
lated, and Reconstituted Wt-CFTR
(A) Silver-stained SDS-PAGE gel showed that
Wt-CFTR is purified to homogeneity prior to recon-
stitution in phospholipid liposomes suitable for
measurement of regulated anion flux through CFTR.
(B) Cartoon representation of the iodide efflux
experiment for purified, reconstituted, and phos-
phorylated Wt-CFTR protein. Proteoliposomes
containing 75mMKI are treated with or without C18,
ATP, and then valinomycin to enable outward diffu-
sion of iodide into a bath containing 75 mM
K-glutamate. Iodide flux through CFTR is monitored
in the solution by an iodide-selectivemicroelectrode.
(C) (i) Pretreatment with 10 mM C18 promoted
channel activation of purified, phosphorylated Wt-
CFTR. Initial iodide efflux traces in the presence of
10 mM C18 (black line) or DMSO (gray line) for a
typical experiment after addition of 1 mM ATP and
20 nM valinomycin. (ii) Bar graphs below show initial
rates of iodide efflux for reconstituted Wt-CFTR
pretreated with 10 mM C18, after addition of 1 mM
ATP and 20 nM valinomycin (black bar), normalized
to an equivalent sample in the absence of C18 but
treated with an equivalent volume of DMSO vehicle
(white bar). Each vehicle or C18 study was normal-
ized relative to the average control or treatment
value, respectively. Data represent the mean of five
(+C18) and four (DMSO) samples; error bars repre-
sent SEMs. The initial flux rates in the presence of
C18 are significantly greater than in the presence of
vehicle (DMSO) alone (*p < 0.05).
(D) (i) C18 promotes channel activity of purified,
phosphorylated Wt-CFTR in the nominal absence of
ATP. Initial iodide efflux traces in the presence of
10 mM C18 (black line) or DMSO (gray line) for a
typical experiment after addition of 20 nM valino-
mycin (no added ATP). (ii) Bar graph shows initial
rates of iodide efflux for reconstitutedWt-CFTRpretreatedwith 10mMC18-/+CFTRinh-172 (20mM), after the addition of 20 nMvalinomycin (blackbar), normalized
to an equivalent sample in the absence of C18 but treated with an equivalent volume of DMSO vehicle (white bar). Each vehicle or C18 study was normalized
relative to the average control or treatment value, respectively. Data represent the mean of four (+C18), three (DMSO), and five (CFTRinh-172) samples,
respectively; error bars represent SEMs. The initial flux rates in the presence of C18 (absence of ATP) are significantly greater than in the presence of vehicle
(DMSO) alone (**p < 0.01) and in the presence of C18 are significantly greater than in the presence of both C18 and CFTRinh-172 (***p < 0.0001).
Chemistry & Biology
Corrector Compounds and Metastable F508del-CFTRIn summary, these studies in primary cultures derived from CF
patients bearing the major mutation confirm that C18 (VRT-534),
a compound that is structurally related to VX-809 and recently
classified as a class 1 corrector compound (Okiyoneda et al.,
2013), mediates partial rescue of the biosynthetic and trafficking
defect caused by F508del. Previously published studies have
also suggested that this effect on mutant protein maturation is
mediated by direct binding during biosynthesis (Loo et al.,
2013; Ren et al., 2013). In the following experiments, we used
an assay of the channel activity of purified full-length Wt and
F508del-CFTR to determine if C18 is also capable of binding
directly to the channel-competent form of the protein.
C18 Modifies Channel Activity of Reconstituted
Wt-CFTR and F508del-CFTR Protein
To determine if C18 interacts directly with CFTR, we assessed
the consequences of C18 addition on the channel activity of
purified and protein kinase A (PKA)-phosphorylated Wt-CFTR
reconstituted in phospholipid liposomes. For these studies, weChemistry & Biology 21,used a novel, rapid purification method for Wt-CFTR that uses
fos-choline 14 detergent to extract protein from Sf9 membranes
prior to purification and reconstitution (Eckford et al., 2012). The
silver-stained gel shows that Wt-CFTR can be purified to near
homogeneity using this method (Figure 2A).
In these studies, proteoliposomes bearing PKA-phosphory-
lated Wt-CFTR were loaded with potassium iodide and then
introduced into an iodide-free buffer to provide a chemical
gradient for iodide efflux. Iodide efflux was continuously
measured using an iodide-sensing microelectrode after the
addition of MgATP to activate the canonical, ATP-dependent
channel activity of phosphorylated CFTR. The potassium-selec-
tive ionophore valinomycin was added abolish charge accumu-
lation and enable the continuous efflux of iodide over time
(Figure 2B). Additives such as C18 or the vehicle (DMSO) were
introduced to the reaction chamber 5min prior to ATP activation.
In Figure 2C, we show that acute pretreatment with C18 (10 mM)
enhanced the initial rate of ATP-dependent iodide efflux
through proteoliposomes bearing phosphorylated Wt-CFTR.666–678, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 669
A Bi
Ci Cii
Bii Figure 3. C18 Binds Directly to Promote
Channel Activation of Phosphorylated and
Reconstituted F508del-CFTR
(A) F508del-CFTR was purified to near homogeneity
following extraction from transfected Sf9 mem-
branes using the detergent PFO. Themutant protein
is stained by Coomassie blue. MW, molecular
weight.
(B) (i) C18 promotes channel activity of phosphory-
lated F508del-CFTR. Left: initial iodide efflux
traces +10 mM C18 (solid black line) or C18
(DMSO; solid gray line) for a typical experiment us-
ing F508del-CFTR purified using the fos-choline 14
method after the addition of 1 mM ATP and 20 nM
valinomycin. Dashed traces show initial iodide efflux
traces +C18 (dashed black line) or C18 (DMSO;
dashed gray line) for an identical experiment as
above but using protein purified by the PFO deter-
gent method. (ii) Initial rates of iodide efflux for
reconstituted F508del-CFTR purified by the fos-
choline 14 and PFO methods treated with 10 mM
C18, after the addition of 1 mM ATP and 20 nM
valinomycin (black bar), normalized to an equivalent
sample in the absence of C18 but treated with an
equivalent volume of DMSO vehicle (white bar).
Data represent the mean of three samples; error
bars represent SEMs. **p = 0.0098, ***p < 0.001.
(C) (i) C18 promotes channel activity of phosphorylated F508del-CFTR in the nominal absence of ATP, and this response is inhibited by CFTRinh-172. Initial iodide
efflux traces +10 mM C18 (black line) or C18 (DMSO; dark gray line) for a typical experiment after the addition of 20 nM valinomycin but in the absence of
ATP. CFTRinh-172 (20 mM; light gray line) prevented flux in F508del-CFTR proteoliposomes. (ii) Initial rates of iodide efflux for reconstituted and phosphorylated
F508del-CFTR treated with 10 mM C18, after the addition of 20 nM valinomycin but in the absence of ATP (black bar), normalized to an equivalent sample in
the absence of C18 but treated with an equivalent volume of DMSO vehicle (white bar). Pretreatment with CFTRinh-172 prevented ATP-independent flux
in control (light gray bars) and C18-treated liposomes (dark gray bars). Data represent the mean of seven (C18CFTRinh-172), 3 (C18+CFTRinh-172), 11
(+C18CFTRinh-172), and five (+C18+CFTRinh-172) samples; error bars represent SEMs. *p < 0.05 versusC18CFTRinh-172, **p < 0.01 forC18+CFTRinh-
172 versus C18CFTRinh-172, and **p < 0.01 for +C18+CFTRinh-172 versus +C18CFTRinh-172.
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Corrector Compounds and Metastable F508del-CFTRAs the reconstitution system contains the Wt-CFTR protein puri-
fied to homogeneity, these proteoliposomal flux studies suggest
that C18 binds directly to the full-length CFTR protein to modify
its channel activity. Interestingly, we found that C18 also
enhanced the channel activity of Wt-CFTR in the nominal
absence of MgATP (Figure 2D), suggesting that pretreatment
with this compound enhances both the canonical, ATP-depen-
dent gatingmechanism and the noncanonical, ATP-independent
gating mechanism of phosphorylated Wt-CFTR. CFTRinh-172
prevented flux by proteoliposomes containing purified Wt-
CFTR, confirming that this activity is conferred by CFTR
(Figure 2Dii).
In the next series of studies, we determined that C18 also in-
teracts directly with purified and reconstituted F508del-CFTR
to enhance its channel activity. As reported in our previous pub-
lications, the major mutant is not purified to homogeneity using
the rapid method used for Wt-CFTR (Eckford et al., 2012). The
molecular basis for this differential detergent extraction efficacy
will be studied in our future work, but we speculate that it may
reflect the larger number of aberrant protein interactions medi-
ated by the mutant protein. Therefore, we used the more strin-
gent purification scheme for F508del-CFTR as described in our
previous work (Wellhauser et al., 2009). In this case, the deter-
gent (perfluoro-octanoic acid [PFO]) was used to solubilize and
purify F508del-CFTR. Figure 3A shows the homogeneity of the
F508del-CFTR protein purified using this method. Following pu-
rification, F508del-CFTR was phosphorylated using PKA and re-670 Chemistry & Biology 21, 666–678, May 22, 2014 ª2014 Elsevierconstituted into phospholipid liposomes. The channel activity of
the mutant protein was assessed as iodide efflux from these
proteoliposomes. As for the Wt-CFTR proteoliposomes, C18
pretreatment was found to enhance the rate of halide flux by pro-
teoliposomes bearing phosphorylated F508del-CFTR relative to
vehicle (DMSO) alone, arguing that C18 directly binds themutant
protein (Figure 3B). We compared the regulated iodide efflux
mediated by PFO-purified F508del-CFTR with F508del-CFTR
extracted from Sf9 membranes using the fast purification
method that uses the more mild detergent, fos-choline 14.
Importantly, regardless of the detergent used, we consistently
observed an increase in the initial rate of iodide efflux following
the addition of C18. Interestingly, we found that C18 also modi-
fied F508del-CFTR-mediated flux in the nominal absence of
ATP, supporting the conclusion that it is not acting exclusively
via the canonical gating pathway. The ATP-independent flux
mediated by F508del-CFTR proteoliposomes in the presence
or absence of C18 was inhibited by the CFTR inhibitor
CFTRinh-172, supporting our claim that the mutant is conferring
this activity (Figure 3C).
Interestingly, we did not detect a significant effect of C18 on
the intrinsic ATPase activity of the full-length, phosphorylated
F508del-CFTR, purified to homogeneity using the PFO method,
solubilized in n-dodecyl b-D-maltoside (DDM) and maintained at
the low concentration of 2 mg/ml (two-way ANOVA, n = 9, Fig-
ure S3), supporting the idea that C18 may not modify gating by
binding to the NBDs. However, further studies are required toLtd All rights reserved
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Corrector Compounds and Metastable F508del-CFTRexamine the C18 dose response and to determine whether the
membrane environment will modify the sensitivity of F508del-
CFTR ATPase activity to C18. Together with the previous studies
on purified Wt-CFTR, these findings support the claim that C18
binds directly to the Wt and F508del-CFTR to modify regions
of the protein engaged in both ATP-independent and ATP-
dependent gating.
C18 Interacts with the F508del-CFTR Protein to Prevent
Its Unfolding and Aggregation In Vitro
We developed an in vitro assay to monitor the ability of small-
molecule corrector compounds to modify the intrinsic instability
of the full-length F508del-CFTR protein and its propensity to un-
fold. It is well known that purified membrane proteins solubilized
in detergent micelles autoassociate and aggregate over time
(Wiener, 2004). The rate of this autoassociation is dependent
on the concentration and fold of the membrane protein (Wiener,
2004). We reasoned that the rate of aggregation of purified
F508del-CFTR in DDM micelles would be faster than the rate
of aggregation of purified Wt-CFTR because of its propensity
to unfold (Clunes et al., 2012; Gentzsch et al., 2007; Okiyoneda
et al., 2010). Our methods for the purification of full-length Wt-
CFTR and the partial purification of full-length F508del-CFTR
from Sf9 cell membranes using the detergent PFO have been
previously described, and we show both proteins as silver-
stained bands following SDS-PAGE analysis in Figure 4A. In
order to compare aggregation propensity, protein-detergent
micelles were concentrated to 2 mg/ml, assessed as absor-
bance at 280 nm. This concentration step initiated aggregation
for themutant protein, and the rate of aggregation wasmeasured
as the loss of absorbance at the wavelength of 280 nm at room
temperature. Figure 4A shows that most of the purifiedWt-CFTR
protein remains in solution for 2 hr after the initiation of aggrega-
tion. On the other hand, no detectable F508del-CFTR protein re-
mained in solution during the same time period after the initiation
of aggregation (Figures 4A and 4B). The relative susceptibility of
the full-length mutant protein to unfold and aggregate was
observed in four independent protein preparations as quantified
in the bar graph shown in Figure 4B. We suggest that the
increased rate of aggregation in this in vitro system reports the
intrinsic instability caused by the F508del mutation in the full-
length CFTR protein. After 5 days, DDM-solubilized F508del-
CFTR protein was still detected as an aggregate on SDS-
PAGE analysis (Figure 4C).
To test the ability of C18 to prevent unfolding and aggrega-
tion of the full-length F508del-CFTR protein in vitro, we added
8 mM C18 or vehicle (DMSO) at the time of the concentration
step used to initiate aggregation. In Figure 4D, we show that
the addition of C18, but not the vehicle (DMSO), significantly
reduced the aggregation propensity of solubilized F508del-
CFTR protein, as evident in the graph and silver-stained gel
of Figure 4D. Analysis of the dose response for the C18-medi-
ated protection yielded a half maximal effective concentration
(EC50) of 7 mM (Figure 4E), close to the dose previously re-
ported for its maximum efficacy in correcting the maturation
defect of F508del-CFTR biosynthesis (Figure S1). Together,
these findings suggest that C18 is directly binding the full-
length F508del-CFTR protein to ameliorate its intrinsic
instability.Chemistry & Biology 21,We compared the efficacy of C18 with that of other chemical
correctors using the aggregation propensity assay. Figure 4F.i
shows monoexponential decay fits for the aggregation data ob-
tained for F508del-CFTR in the presence of other correctors (all
at 8 mM) and negative controls. To aid in visualizing the data, the
curves fitted to the data for the negative control (DMSO) and data
for C18-treated protein samples from Figure 4D were superim-
posed on the graph showing the effects of other corrector com-
pounds. These curves were generated using three or four
different protein preparations of F508del-CFTR. VRT-325 is a
first-generation chemical corrector that we previously showed
to bind directly to F508del-CFTR (Kim Chiaw et al., 2010).
VRT-325, but not its inactive analog (InVRT-325, provided as a
gift by Vertex Pharmaceuticals) delayed the aggregation of
F508del-CFTR. At 1 hr after the initiation of aggregation, there
was significantly more F508del-CFTR remaining in solution
than in preparations treated with DMSO alone (Figure 4Fii, *p <
0.05). Similarly, the addition of VX-809 (8 mM) exerted a stabiliz-
ing effect on F508del-CFTR protein in this assay (Figures 4Fi and
4Fii). These results suggest that C18, VX-809, and VRT-325
interact with the full-length mutant protein to ameliorate its un-
folding and aggregation (Figures 4Fi and 4Fii). It remains strictly
possible, though unlikely in our view, that these compounds
exert a nonspecific detergent-like effect on the protein rather
than a specific binding interaction. We view this as unlikely
because these small molecules are added at a much lower con-
centration than the DDM present in the solution and thus are un-
likely to form detergent-like micelles.
The Class 1 Corrector Compounds C18 and VX-809
Interact with F508del-CFTR after Its Rescue to the Cell
Surface to Enhance Its Stability
The aforementioned in vitro assay prompted the hypothesis that
certain corrector compounds, including those classified as class
1 correctors in a recent paper by Okiyoneda et al. (2013), may
exert multiple effects on the F508del-CFTR protein. In addition
to the rescue of F508del-CFTR misfolding and mistrafficking
during biosynthesis and processing, these compounds may
also exert an acute effect posttranslationally by binding and sta-
bilizing a native state of the full-length mutant protein or, alterna-
tively, by binding to a metastable intermediate to induce a
relatively native conformer. Therefore, we were prompted to
determine if the corrector compounds (C18 and VX-809) exerted
an acute effect on the full-length mutant protein in cells. In these
experiments, F508del-CFTR stably expressed in BHK cells was
temperature ‘‘corrected’’ at 27C to partially correct the folding
and processing defect. We ‘‘rescued’’ the folding defect by
low-temperature treatment rather than pharmacologically in or-
der to clearly differentiate the chronic versus acute effects of
‘‘corrector’’ compounds.
After the temperature rescue of F508del-CFTR stably ex-
pressed in BHK cells, the experiment was initiated by adding
VX-809 (n = 4), C18 (n = 2, not shown), or the vehicle (DMSO)
to the cell bath and reexposing cultures to 37C. Cyclohexamide
was added at the same time as the corrector compounds to pre-
vent protein synthesis immediately prior to reexposure to 37C.
F508del-CFTR protein abundance (both band B and band C)
was monitored for 8 hr. Figure S4A shows that, as expected,
F508del-CFTR protein is rapidly degraded over this time relative666–678, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 671
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B C Figure 4. Purified F508del-CFTR Exhibits
Enhanced Aggregation Propensity Relative
to Wt-CFTR In Vitro
(A) Silver-stained gels show the abundance of Wt
or F508del-CFTR protein before and 2 hr after the
induction of a concentrating step to enhance ag-
gregation propensity. Wt-CFTR protein remains
soluble 2 hr after the initiation of the concentrating
step, as evident in the silver-stained SDS-PAGE
analysis. On the other hand, F508del-CFTR pro-
tein, after a similar concentrating step, is not
detectable in SDS-PAGE after 2 hr, pointing to its
propensity to aggregate and become insoluble.
(B) The bar graph shows the percentage of Wt or
mutant CFTR remaining in solution (absorbance at
280 nm) for the two genotypes. The two genotypes
are significantly different with respect to their ag-
gregation propensity (*p < 0.05, n = 3); error bars
represent SEMs.
(C) Silver-stained gel shows that F508del-CFTR
protein is detectable as a smear containing ag-
gregates after 5 days.
(D) The line graph shows the kinetics for the
disappearance of purified F508del-CFTR in DDM
micelles in the presence of vehicle (DMSO, open
boxes) or C18 (8 mM, solid boxes). Each symbol
indicates the mean and the SEM for four inde-
pendent trials. The inset shows that the addition of
C18 (but not DMSO) protects the mutant protein
from aggregation and precipitation for 2 hr after
the concentration step to initiate aggregation.
(E) The ability of C18 addition to prevent the ag-
gregation of detergent-solubilized F508del-CFTR
exhibits dose dependency, with an EC50 of 7 mM;
error bars represent SEMs. OD, optical density.
(F) (i) Monoexponential fits of the rate of F508del-
CFTR protein loss following the initiation of ag-
gregation and the effect of various additives,
including the correctors: C18 (line fit of Figure 5A),
VX-809, VRT-325, and negative controls, including
an inactive analog of VRT-325 (InVRT-325) and the
vehicle (DMSO, line fit of Figure 4D). The data
shown for VX-809, VRT-325, and InVRT-325 were
obtained from a minimum of three or four distinct
studies, each using different purifications of
F508del-CFTR; error bars represent SEMs. The
tau values derived from eachmonoexponential fit correspond to the relative efficacy of each additive to slow the rate of full-length F508del-CFTR aggregation and
precipitation (C18tau = 155 min [r
2 = 0.81] > VX-809tau = 70 min [r
2 = 0.81] > VRT-325tau = 41 min [r
2 = 0.71] > InVRT-325tau = 19 min [r
2 = 0.8] > DMSOtau = 15 min
[r2 = 0.72]). (ii) The bars show the mean ± SEM of the percentage F508del-CFTR remaining soluble 1 hr after initiation of the aggregation assay in the presence of
the various additives. The addition of VRT-325, VX-809, and C18 exerted a significant positive effect (*p < 0.05 and **p < 0.01) in protecting F508del-CFTR from
aggregation.
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Corrector Compounds and Metastable F508del-CFTRto its abundance at time zero (Gentzsch et al., 2004; Okiyoneda
and Lukacs, 2012). Notably, the addition of VX-809 delays the
rate of degradation of the mature band C form of the protein
but not the band B form (Figures S4A–S4C, n = 4). Whereas
70% of the band C form of the rescued F508del-CFTR protein
had degraded by 4 hr in the absence of VX-809, only 40% had
degraded in the presence of VX-809. A similar trend was
observed in studies using C18 instead of VX-809, with 40%
less band C protein being degraded in the presence of C18
(n = 2, not shown). These findings support the hypothesis that
posttranslationally, VX-809 exerts an acute effect to stabilize
and/or induce a native stable conformation in the rescued,
mature form of F508del-CFTR.672 Chemistry & Biology 21, 666–678, May 22, 2014 ª2014 ElsevierClass 1 Corrector Compounds Interact with F508del-
CFTR after Its Rescue to the Cell Surface to Enhance Its
Channel Activation
The results of the proteoliposomal flux assay of purified and
PKA-phosphorylated F508del-CFTR protein also support the hy-
pothesis that certain corrector compounds have multiple activ-
ities. We were prompted to test the hypothesis that in addition
to rescuing the primary defect in folding caused by F508del-
CFTR, C18 and VX-809 also act acutely to induce and/or stabi-
lize the channel-competent form of the phosphorylated mutant
after rescue of the folding defect in cells. To test this hypothesis
in cells, we used a fluorescence-based assay of chloride flux
(the 6-methoxy-N-[3-sulfopropyl]-quinolinium [SPQ] assay) andLtd All rights reserved
Figure 5. Acute Pretreatment of Tempera-
ture-Rescued F508del-CFTR in BHK Cells
with C18, VX-809, and VX-661 Promotes
Channel Activation
(A) (i) representative traces of SPQ dequenching
mediated by chloride efflux from BHK cells ex-
pressing F508del-CFTR and grown at low tem-
perature (27C). Cells were treated with 6 mM
C18 (orange), 3 mM VX-809 (blue), or DMSO
(gray, black) at the stippled arrow labeled ‘‘Pre-
treat’’ and subsequently treated with 10 mM
forskolin (FSK) (or DMSO in the unstimulated
condition, gray) at 4 min (solid arrow, ±FSK). At
28 min, the extracellular, nitrate-containing so-
lution was replaced with Hank’s balanced salt
solution, resulting in rapid chloride-mediated
SPQ quenching. These representative traces
show the mean of triplicate studies plus the SD.
(ii) Bar graph shows a summary of the mean ±
SEM rates of change in relative fluorescence
units (RFU) over the first 4 min of stimulation,
normalized to the RFU change in cells pretreated
with DMSO and stimulated with 10 mM FSK
(labeled DMSO, n = 7). Each n represents a
distinct cell plating. Significant enhancement of
FSK-mediated efflux is evident in experiments
pretreated with correctors C18 (n = 7), VX-809
(n = 8), and VX-661 (3 mM, n = 3) but not with the
corrector Corr 4a (10 mM, n = 3, green). The red
bar represents the efflux rate conferred by
stimulation with 10 mM FSK and 1 mM VX-770 (n = 9). Asterisks signify significant differences from the vehicle control (DMSO) (**p < 0.01, ***p < 0.001).
(B) (i) Immunoblot confirms that VX-661, a new corrector compound in clinical trials, is also effective in partially correcting the processing defect in F508del-
CFTR, stably expressed in BHK cells and grown at 37C for 24 hr. (ii) The ratio of C band relative to bands C and B is significantly enhanced in three
independent studies (*p < 0.05); error bars represent SEMs.
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CFTR function in BHK cells stably expressing themutant protein.
We tested the acute effect of C18 on the channel activity of
F508del-CFTR after rescue of the mutant protein to the cell sur-
face by low-temperature culture conditions. C18 was added as a
pretreatment 5 min prior to activation with forskolin in the cell-
based assay, because this proceduremore closely recapitulated
the experiments performed in the reconstitution system. As
shown in Figures 5Ai and 5Aii, treatment with C18 (orange)
caused no response on its own (prior to forskolin addition and
F508del-CFTR phosphorylation). On the other hand, pretreat-
ment with C18 significantly enhanced the forskolin-mediated
chloride flux response. Similarly, acute pretreatment with struc-
turally related correctors (i.e., VX-809 [blue] and VX-661 [pale
yellow, with its activity as a corrector documented in Figure 5Bii])
enhanced the response of temperature-rescued F508del-CFTR
to forskolin. Therefore, these studies show that in addition to
their ‘‘corrector’’ activity in partially rescuing the protein folding
and trafficking defect of F508del-CFTR, these structurally
related compounds, C18, VX-809, and VX-661, act acutely to
‘‘prime’’ or ‘‘potentiate’’ the phosphorylation-dependent regula-
tion of F508del-CFTR channel activity at the cell surface. Inter-
estingly, the ‘‘corrector’’ 4a (C4), recently proposed to act
through a molecular mechanism distinct from those of C18 and
VX-809 (Okiyoneda et al., 2013), fails to mediate such an acute
effect on channel function (Figure 5Aii).
There are certain differences between the acute effects of C18
and VX-809 and the acute effect mediated by VX-770 on channelChemistry & Biology 21,activity. First, the increase in forskolin-mediated channel activity
of cell surface F508del-CFTR caused by VX-770 is approxi-
mately twice that observed for C18 and VX-809 in our assay sys-
tem (Figure 5Aii). Further, unlike the response to VX-770, which
occurs immediately after its addition, C18 and VX-809 require
a pretreatment period of approximately 5 min. When C18 and
VX-809 are added simultaneously with forskolin, the fold in-
crease over forskolin alone is not statistically significant, with
changes in initial slopes of only 1.02 ± 0.273 and 1.02 ± 0.224,
respectively (nR 3). It is not known why this pretreatment period
for C18 and VX-809 is required in cells. We speculate that the
latency of the ‘‘priming’’ or ‘‘potentiating’’ effect of C18 and
VX-809 relative to VX-770 reflects the relative lipid partition coef-
ficients (i.e., VX-770 [ClogP = 5.0] vs. C18 [ClogP = 3.6] and VX-
809 [ClogP = 4.2] (http://www.vcclab.org/lab/alogps).
Assessment of Competition between the ‘‘Acute’’ Effect
of These Correctors and the Potentiation Mediated by
VX-770
In order to determine whether C18 and VX-809 could mediate
their effects on channel function through a similar binding site
as VX-770, we assessed the potential additivity of their effects
on the activation of F508del-CFTR in BHK cells. In Figure 6A,
we show that, at least using the concentrations previously found
to be optimal in this system, pretreatment with C18 did not
modify the subsequent potentiation by VX-770. This finding sug-
gests that C18 does notmediate its acute ‘‘priming’’ effect on the
channel activity of temperature-rescued F508del-CFTR through666–678, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 673
Figure 6. No Evidence for Competition be-
tween Corrector Compounds and the
Potentiator VX-770
(A) (i) Representative traces from the SPQ assay
measuring chloride efflux from BHK cells ex-
pressing F508del-CFTR at 27C and pretreated
with C18 (orange and magenta) or vehicle (black
and red). Although pretreatment with C18 (6 mM)
improved forskolin (10 mM) mediated efflux chlo-
ride from F508del-CFTR transfected cells (black
vs. orange), it did not modify the potentiation by
VX-770 (0.1 mM) and forskolin (10 mM) (red vs.
magenta). Mean + SD of triplicate studies is
shown. (ii) Bars show that no significant difference
is induced by C18 pretreatment in VX-770 and
forskolin-mediated potentiation in three indepen-
dent studies; error bars represent SEMs.
(B) (i) As shown previously, the processing defect
of F508del-CFTR is partially corrected by C18
(6 mM) and VX-809 (3 mM) in stably transfected
BHK cells at 37C after 24 hr. This correction leads
to the accumulation of band C (open triangle)
relative to band B (solid triangle). Simultaneous
addition of VX-770 does not significantly alter
processing enhanced by C18. (ii) The adjacent bar
graphs show the aggregate data for three inde-
pendent studies. Asterisks signify significant dif-
ferences from the vehicle control (DMSO) (*p <
0.05, **p < 0.01); error bars represent SEMs.
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Corrector Compounds and Metastable F508del-CFTRthe potentiation site used by VX-770. Conversely, there was no
apparent interaction between VX-770 and C18 or VX-809 in
longer term (24 hr) studies of F508del-CFTR processing from
band B to band C (Figure 6B).
Acute Effect of Class 1 Correctors in Enhancing
F508del-CFTR Channel Activation after Temperature
Rescue Also Observed in Patient-Derived Intestinal
Organoids
In the following studies, we determined if C18 and VX-809 ex-
erted an acute effect in ‘‘priming’’ the channel activity of
‘‘rescued’’ F508del-CFTR, endogenously expressed in patient-
derived tissues. An assay of CFTR function based on forskolin-
induced swelling of patient-derived rectal organoids has been
described (Dekkers et al., 2013). Here we show that acute pre-
treatment with C18 or VX-809 also enhanced forskolin-induced
swelling of intestinal organoids obtained from three different pa-
tients homozygous for F508del-CFTR. Figure 7 shows images of
calcein-AM-loaded organoids in which F508del-CFTR had been
previously rescued with low temperature, at 27C for 24 hr. The
first panel shows themodest response to forskolin after pretreat-
ment with the negative control (DMSO) (Figure 7A). Acute pre-
treatment of the organoids with C18 (orange) or VX-809 (blue)
for 15 to 30 min caused a significant increase in the swelling
response to forskolin (albeit less than the response to the poten-
tiator VX-770; red) (Figures 7B and 7C). This ‘‘priming’’ or poten-
tiating effect was not observed in intestinal organoids generated
from a patient bearing a CFTR nonsense mutation (E60X/4015674 Chemistry & Biology 21, 666–678, May 22, 2014 ª2014 ElsevierdelATT, inset) showing that it is mediated by rescued F508del-
CFTR rather than a non-CFTR channel. It is not clear why a
longer pretreatment time is required in the organoid experiments
than the BHK cell experiments, but we reason that it may relate
to the relatively viscous properties of the Matrigel (Corning) ma-
trix in which the organoids are grown. In summary, we found that
C18 and VX-809 induced amodest but significantly ‘‘priming’’ ef-
fect on forskolin-mediated activation of rescued F508del-CFTR
protein in patient-derived tissues.
DISCUSSION
The term ‘‘corrector’’ is typically used to describe compounds
that rescue the folding defect of F508del-CFTR, permitting its
forward trafficking through the biosynthetic pathway and partial
functional expression on the cell surface. This classification can
include compounds that modify the folding environment (Wang
et al., 2006) as well as compounds such as VX-809 and C18
that likely interact directly to modify folding and conformational
maturation during synthesis. On the other hand, the term ‘‘poten-
tiator’’ is typically used to describe compounds that enhance the
activation of F508del-CFTR by forskolin after its rescue to
the cell surface. Pedemonte et al. (2011) were the first to coin
the term ‘‘dual-acting potentiator-correctors’’ to describe those
compounds with both activities. Our studies suggest that VX-
809 and C18 may fall into this latter category. Although both of
these corrector compounds exert a primary action in rescuing
the folding and assembly of F508del-CFTR cotranslationally,Ltd All rights reserved
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Figure 7. Corrector Compounds Exert an
Acute Effect to Enhance Forskolin-Induced
Swelling by F508del/F508del Rectal Organo-
ids at 27C
(A) Representative confocal microscopic images
showing forskolin-induced swelling (FIS) of calcein
green-labeled F508del-CFTR organoids at 27C at
60 min. Organoids were pretreated with DMSO,
6 mMC18, 6 mMVX-809, or 1 mMVX-770 for 30min
prior to forskolin (5 mM) activation. Scale bars
represent 140 mm.
(B) Time courses for increase in FIS (relative to t =
0) for F508del-CFTR organoids pretreated as
described in (A), mean ± SEM.
(C) Quantification of FIS in organoids pretreated for
30 min with DMSO, C18, VX-809, or VX-770 at
27C. Each bar represents FIS expressed as ab-
solute area under the curve calculated from time
lapses as presented in (B) (baseline = 100%, t =
60 min) normalized to DMSO-treated organoids
and averaged from four independent experiments
using organoids derived from three different
F508del-CFTR subjects (mean ± SEM). Significant
enhancement of FIS observed for C18, VX-809,
and VX-770 pretreatment (*p < 0.05). The inset
shows that there is no augmentation of swelling by
these compounds in organoids derived from a CF
patient bearing a nonsense mutation (E60X/4015
delATT).
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Corrector Compounds and Metastable F508del-CFTRas shown in previous publications (Farinha et al., 2013; Loo et al.,
2013; Okiyoneda et al., 2013; Ren et al., 2013), the current study
shows that they also exert a secondary, posttranslational activity
to acutely stabilize and or enhance the channel-active form of the
metastable F508del-CFTR protein after its biosynthetic rescue.
In the current work, we assessed the acute ‘‘potentiating’’ or
‘‘priming’’ effects of compounds after low-temperature correc-
tion of the folding defect of F508del-CFTR. The rationale for
our strategy was to functionally separate acute ‘‘potentiation’’
effects from the long-term effects of these compounds on pro-
tein folding. Importantly, we do make the assumption that the
temperature-corrected F508del-CFTR and the compound-cor-
rected mutant protein respond similarly to compound binding
at the cell surface. The development of a ‘‘binding assay’’ per
se (to complement our activity assays) would help in testing
this assumption directly, and this constitutes a major goal of
our future work.
Future Studies Using Purified, Full-Length CFTR Will
Lead to Discovery of the Binding Site for Correctors
such as VX-809, C18, and VX-661
To date, corrector binding assays have been conducted using
isolated CFTR-NBD1 (Hudson et al., 2012; Sampson et al.,
2011) or in silico, using drug-docking algorithms in conjunction
with molecular models of the full-length CFTR protein (He
et al., 2013; Kalid et al., 2010). In silico docking studies of
the corrector VX-809 implicated a possible binding site at
the NBD1-ICL4 interface (He et al., 2013). Recent studies of
aminoterminal fragments of F508del-CFTR suggest that VX-
809 binds to MSD1 to enhance assembly during synthesis
(Loo et al., 2013; Ren et al., 2013). Clearly, there remains
considerable uncertainty regarding the identity of the bindingChemistry & Biology 21,site (or sites) for these partially effective ‘‘corrector’’ com-
pounds. The current studies show that the corrector com-
pounds C18 and VX-809 interact directly with the full-length
F508del-CFTR protein. Hence, these findings provide a
compelling rationale for future experiments using purified,
full-length F508del-CFTR protein as a discovery platform to
define the molecular basis for pharmacological rescue of the
major CF-causing mutant.
SIGNIFICANCE
The efficacy of the corrector compounds VX-809 and VX-661
is thought to solely reflect the rescue of defective F508del-
CFTR folding and trafficking from the endoplasmic reticu-
lum to the plasma membrane. The current studies suggest
that rescue also reflects the ability of this class of corrector
compounds to interact directly with the metastable mutant
after its partial rescue to the cell surface. Acute pretreat-
ment with these compounds enhanced the activation of
F508del-CFTR channels previously rescued to the cell sur-
face by low temperature. Hence, these compounds act
both cotranslationally and posttranslationally. We suggest
that the acute effect of the class of correctors is reporting
a stabilization and or induction of the channel-competent
conformer of the metastable, full-length mutant protein.
This acute effect is secondary to the primary, cotranslational
activity of these compounds. Importantly, the effect of these
compounds on channel activity is modest compared with
the potentiation observedwith VX-770. However, our studies
will prompt further evaluation of the role of this secondary,
posttranslational activity in the clinical efficacy of this class
of compounds.666–678, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 675
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Cell Lines
BHK cells stably transfected with F508del-CFTR were obtained from
Dr. Lukacs (McGill University, Montreal, QC, Canada; Sharma et al., 2004).
GripTite (Life Technologies) human embryonic kidney 293 cells stably trans-
fected with F508del-CFTRwere obtained fromDr. Rotin (Hospital for Sick Chil-
dren, Toronto, ON, Canada; Trzcinska-Daneluti et al., 2009).
Electrophysiological Studies
Isc wasmeasured using Ussing chambers (Physiologic Instruments). Buffer so-
lutions containing physiological and symmetrical chloride concentrations in
both apical and basolateral chambers were maintained at 37C and continu-
ously bubbled with 95% O2/5% CO2.
Wt-CFTR and F508del-CFTR Purification for Aggregation Propensity
Assay
The method for purification of CFTR (Wt) from transfected Sf9 cells using PFO
was described previously (KimChiaw et al., 2010;Wellhauser et al., 2009), with
modifications described in Supplemental Experimental Procedures. The pro-
tein was phosphorylated at 4C overnight in the presence of 2 mM ATP,
5 mM Mg, and 200 nM PKA catalytic subunit prior to initiation of the aggrega-
tion assay.
Aggregation Propensity Assay
To begin the aggregation assay, the <0.2 mg/ml protein was concentrated to
2 mg/ml at 4C. Small-molecule treatments (C18, etc.) or DMSO vehicle con-
trol was added as 1 ml aliquots of the stock at the appropriate concentration to
49 ml samples of concentrated, purified protein (final DMSO concentration
2%). Samples were brought to room temperature and the absorbance of
2 ml aliquots was read at time intervals ranging from 5 to 60 min on an Epoch
Microplate Spectrophotometer using the Take3 microvolume plate (BioTek).
The absorbance of control samples containing identical concentrations of
drug in washing buffer was subtracted from that of the protein-containing
samples.
Wt-CFTR and F508del-CFTR Purification for Functional
Reconstitution
Wt-CFTR and F508del-CFTR were extracted from transfected Sf9 cells using
the rapid, fos-choline 14-dependent method (Eckford et al., 2012) for proteo-
liposomal flux studies. Wt-CFTR, purified to homogeneity using this method
and phosphorylated by PKA and ATP, was reconstituted into 5mg of amixture
of chicken egg phosphatidylcholine (Avanti Polar Lipids) at a ratio of 1:200 to
1:1200 (protein/lipid, w/w) by incubation in the presence of DDM and 75 mM
KI for 30 min, followed by passage through a detergent-binding spin column
(Pierce). F508del-CFTRwas enriched but not purified using thismethod; there-
fore, the PFO purification method was also use where indicated to purify
F508del-CFTR prior to its functional reconstitution in lipids as described
previously.
Proteoliposomal Flux Assay
Small molecules, at a final concentration of 10 to 20 mM, or vehicle was added
5 min before the initiation of flux (final DMSO concentration 0.17%). Samples
were treated with or without 1 mM final-concentrationMg-ATP and with 20 nM
valinomycin to initiate iodide flux.
Forskolin-induced Organoid Swelling Assay
Crypt isolation and culture of human intestinal cells in Matrigel have been
described previously (Sato et al., 2011). The medium was refreshed every 2
to 3 days, and organoids were passaged 1:4 every 7 to 10 days. Organoids
from passages 5 to 15 were used for confocal live-cell imaging. Organoids
from a 7-day-old culture were seeded in a flat-bottom 96-well culture plate
(Nunc; Thermo Scientific) in 5 ml Matrigel commonly containing 20 to 80 orga-
noids and 100 ml culture medium (Dekkers et al., 2013). One day after seeding,
organoids were incubated for 30min with 100 ml standard culturemedium con-
taining 2 mMcalcein-green (Invitrogen) in combination with DMSO, C18 (6 mM),
VX-809 (6 mM), or VX-770 (6 mM). After compound treatment, 5 mM forskolin
was added, and organoids were directly analyzed by confocal live-cell micro-676 Chemistry & Biology 21, 666–678, May 22, 2014 ª2014 Elsevierscopy (LSM 710; Carl Zeiss) (53 objective). Three or four wells were used per
condition.
Statistical Analyses
Paired t tests were used in single comparisons, and p values < 0.05 were
considered statistically significant. One-way ANOVA followed by the Bonfer-
roni posttest was used to define statistically significant differences among
multiple experimental groups.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2014.02.021.
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